Physician profile
David D Song
NPI 1679599765
$5,294.47
in general payments reported to CMS, 2019-2025
19 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.67 · 2021: $686 · 2022: $299 · 2023: $1,127 · 2024: $1,691 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,383 · Consulting Fee: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,382.82 |
| Consulting Fee | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,996.64 | 2021-2025 | General - Dbs |
| Abbott Laboratories | $1,939.57 | 2022-2025 | Esprit, Diamondback Peripheral, Supera |
| Abbvie INC. | $411.40 | 2022-2025 | Botox |
| Acadia Pharmaceuticals INC | $160.07 | 2025 | Nuplazid |
| Tg Therapeutics, INC. | $124.99 | 2024 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2021 | |
| Grifols USA, LLC | $104.93 | 2024 | Gamunex-C |
| Ucb, INC. | $92.96 | 2025 | Rystiggo |
| Allergan, INC. | $71.17 | 2021-2022 | |
| Livanova USA, INC. | $55.59 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Merz Pharmaceuticals, LLC | $37.76 | 2025 | Xeomin |
| Neurocrine Biosciences, INC. | $35.35 | 2025 | |
| Mdd US Operations, LLC | $33.92 | 2025 | Gocovri |
| Tanabe Pharma America, INC. | $32.65 | 2024 | |
| Esperion Therapeutics, INC. | $26.67 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $26.15 | 2025 | |
| Astellas Pharma US INC | $18.83 | 2021 | |
| Travere Therapeutics, INC. | $0.83 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.